Date: 12-24-20	023
Your Name:	Wenchao Zhao
Manuscript Tit	le: Hepatic arterial infusion chemotherapy combined with bevacizumab plus PD-1 inhibitor for
gallbladder ca	ncer with hepatic oligometastasis: a real-world study.
Manuscrint nu	mber (if known): ICO-23-816

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ X _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	X_None	
4	Consulting fees	X _None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	X_None	
	educational events		
6	Payment for expert testimony	X _None	
7	Support for attending meetings and/or travel	_ X _None	
8	Patents planned, issued or pending	_ X _None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ X _None	
10	Leadership or fiduciary role	V Name	
10	in other board, society, committee or advocacy	X _None	
	group, paid or unpaid		
11	Stock or stock options	_ X _None	
12	Receipt of equipment,	_ X _None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ X _None	
	financial interests		

None			

Please place an "X" next to the following statement to indicate your agreement:

Date: 12-24-20)23
Your Name:	Zhiyuan Yao
Manuscript Tit	le: Hepatic arterial infusion chemotherapy combined with bevacizumab plus PD-1 inhibitor for
gallbladder ca	ncer with hepatic oligometastasis: a real-world study.
Manuscrint nu	mber (if known): ICO-23-816

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ X _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	X_None	
4	Consulting fees	X _None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	X_None	
	educational events		
6	Payment for expert testimony	X _None	
7	Support for attending meetings and/or travel	_ X _None	
8	Patents planned, issued or pending	_ X _None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ X _None	
10	Leadership or fiduciary role	V Name	
10	in other board, society, committee or advocacy	X _None	
	group, paid or unpaid		
11	Stock or stock options	_ X _None	
12	Receipt of equipment,	_ X _None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ X _None	
	financial interests		

None			

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>12-24-2</u>	2023
Your Name:	Jingbo Li
Manuscript Ti	tle: Hepatic arterial infusion chemotherapy combined with bevacizumab plus PD-1 inhibitor for
gallbladder c	ancer with hepatic oligometastasis: a real-world study.
Manuscrint n	umber (if known): ICO-23-816

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ X _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	X_None	
4	Consulting fees	X _None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X_None	
6	Payment for expert testimony	_ X _None	
7	Support for attending meetings and/or travel	_ X _None	
8	Patents planned, issued or pending	_ X _None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ X _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ X _None	
11	Stock or stock options	X _None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	_ X _None	

None			

Please place an "X" next to the following statement to indicate your agreement:

Date: 12-24-2	023
Your Name:	Wenping Li
Manuscript Tit	le: Hepatic arterial infusion chemotherapy combined with bevacizumab plus PD-1 inhibitor for
gallbladder ca	ncer with hepatic oligometastasis: a real-world study.
Manuscrint nu	mber (if known): ICO-23-816

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ X _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	X_None	
4	Consulting fees	X _None	

5	Payment or honoraria for	_ X _None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	_ X _None	
	testimony		
7	Support for attending	V None	
'	meetings and/or travel	_ X _None	
	g ,		
8	Patents planned, issued or	_ X _None	
	pending		
_			
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ X _None	
10	Leadership or fiduciary role	_ X _None	
10	in other board, society, committee or advocacy	_ X _None	
	group, paid or unpaid		
11	Stock or stock options	X _None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	_ ^ _None	
	writing, gifts or other		
	services		
13	Other financial or non-	_ X _None	
	financial interests		

None			

Please place an "X" next to the following statement to indicate your agreement:

Date: 12-24-20	023
Your Name:	Qi Dou
Manuscript Tit	le: Hepatic arterial infusion chemotherapy combined with bevacizumab plus PD-1 inhibitor for
gallbladder ca	ncer with hepatic oligometastasis: a real-world study.
Manuscript nu	mber (if known): JGO-23-816

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ X _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	X_None	
4	Consulting fees	_ X _None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X_None	
6	Payment for expert testimony	_ X _None	
7	Support for attending meetings and/or travel	_ X _None	
8	Patents planned, issued or pending	_ X _None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ X _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ X _None	
11	Stock or stock options	X _None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	_ X _None	

None			

Please place an "X" next to the following statement to indicate your agreement:

Date: 12-24-2	023
Your Name:	Xiangfei Zhao
Manuscript Ti	tle: Hepatic arterial infusion chemotherapy combined with bevacizumab plus PD-1 inhibitor for
gallbladder ca	ancer with hepatic oligometastasis: a real-world study.
Manuscript nu	umber (if known): JGO-23-816

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ X _None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ X _None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ X _None	
4	Consulting fees	_ X _None	

5	Payment or honoraria for	_ X _None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	_ X _None	
	testimony		
7	Support for attending	X _None	
,	meetings and/or travel	XNone	
8	Patents planned, issued or	_ X _None	
	pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ X _None	
10	Leadership or fiduciary role	V Name	
10	in other board, society, committee or advocacy	_ X _None	
g			
	group, paid or unpaid		
11	Stock or stock options	_ X _None	
12	Descript of anythrough	V	
12	Receipt of equipment, materials, drugs, medical	_ X _None	
	writing, gifts or other		
	services		
13	Other financial or non-	_ X _None	
	financial interests		

None			

Please place an "X" next to the following statement to indicate your agreement:

Date: 12-24-2	023
Your Name:	Yintao Wu
Manuscript Tit	tle: Hepatic arterial infusion chemotherapy combined with bevacizumab plus PD-1 inhibitor for
gallbladder ca	ancer with hepatic oligometastasis: a real-world study.
Manuscrint nu	umber (if known): ICO-23-816

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ X _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X _None	
3	Royalties or licenses	X_None	
4	Consulting fees	_ X _None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X_None	
6	Payment for expert testimony	X _None	
7	Support for attending meetings and/or travel	_ X _None	
8	Patents planned, issued or pending	_ X _None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_ X _None	
11	Stock or stock options	X _None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	_ X _None	

None			

Please place an "X" next to the following statement to indicate your agreement:

Date: 12-24-20	023
Your Name:	Nianxin Xia
Manuscript Tit	le: Hepatic arterial infusion chemotherapy combined with bevacizumab plus PD-1 inhibitor for
gallbladder ca	ncer with hepatic oligometastasis: a real-world study.
Manuscript nu	mber (if known): <u>JGO-23-816</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ X _None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ X _None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ X _None	
4	Consulting fees	_ X _None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	X_None	
	educational events		
6	Payment for expert testimony	X _None	
7	Support for attending meetings and/or travel	_ X _None	
8	Patents planned, issued or pending	_ X _None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ X _None	
10	Leadership or fiduciary role	V Name	
10	in other board, society,	X _None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ X _None	
12	Receipt of equipment,	_ X _None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ X _None	
	financial interests		

None			

Please place an "X" next to the following statement to indicate your agreement: